A PHASE 3, RANDOMIZED OPEN-LABEL STUDY OF PEMBROLIZUMAB (MK-3475) PLUS OLAPARIB VERSUS ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO ARE UNSELECTED FOR HOMOLOGOUS RECOMBINATION REPAIR DEFECTS AND HAVE FAILED PRIOR TREATMENT WITH ONE NEXT-GENERATION HORMONAL AGENT (NHA) AND CHEMOTHERAPY (KEYLYNK-010)

Registry ID

MK-7339-010

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2021-10-21

Last update

2019-04-03

Conditions

• CASTRATION RESISTANT PROSTATE CANCER

Related clinical trials

• A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF GSK5458514 PSMA TARGETING T CELL ENGAGER ALONE OR IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN ADULT PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
• A MULTINATIONAL, MULTICENTER, PROSPECTIVE, RANDOMIZED, CONTROLLED, OPENLABEL, PHASE 3 STUDY OF LUTETIUM (177LU) ROSOPATAMAB TETRAXETAN IN COMBINATION WITH STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) AFTER ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) TREATMENT
• A PHASE 3, TWO-PART, RANDOMIZED, OPEN-LABEL, ADAPTIVE STUDY COMPARING BMS- 986365 VERSUS INVESTIGATOR'S CHOICE OF THERAPY COMPRISING EITHER DOCETAXEL OR SECOND ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI), IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) - RECHARGE
• A RANDOMIZED PHASE III CLINICAL TRIAL FOR THE ADDITION OF DOCETAXEL TO ANDROGEN RECEPTOR PATHWAY INHIBITORS IN PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER AND SUBOPTIMAL PSA RESPONSE (TRIPLE-SWITCH)
• SATISFACTION: A PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY OF [225AC]AC-PSMA-R2 IN MEN WITH HEAVILY PRE-TREATED PSMA POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH OR WITHOUT PRIOR 177LU-LABELLED PSMA-TARGETED RADIOLIGAND THERAPY
• OPTION-DDR: A RANDOMIZED PHASE III TRIAL INVESTIGATING PLATINUM AND TAXANE CHEMOTHERAPY IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH ALTERATIONS IN DNA DAMAGE RESPONSE (DDR) GENES

View on source registry